Reilly Financial Advisors LLC Grows Stock Position in Celgene Co. (NASDAQ:CELG)

Reilly Financial Advisors LLC boosted its stake in shares of Celgene Co. (NASDAQ:CELG) by 43.6% during the 3rd quarter, according to its most recent 13F filing with the SEC. The firm owned 1,071 shares of the biopharmaceutical company’s stock after buying an additional 325 shares during the period. Reilly Financial Advisors LLC’s holdings in Celgene were worth $106,000 at the end of the most recent quarter.

Other large investors also recently added to or reduced their stakes in the company. Renaissance Technologies LLC increased its stake in Celgene by 85.7% in the second quarter. Renaissance Technologies LLC now owns 8,935,785 shares of the biopharmaceutical company’s stock worth $826,024,000 after purchasing an additional 4,122,685 shares during the period. Nuveen Asset Management LLC increased its stake in Celgene by 707.3% in the second quarter. Nuveen Asset Management LLC now owns 4,476,814 shares of the biopharmaceutical company’s stock worth $413,836,000 after purchasing an additional 3,922,247 shares during the period. York Capital Management Global Advisors LLC increased its stake in Celgene by 854.8% in the second quarter. York Capital Management Global Advisors LLC now owns 2,588,825 shares of the biopharmaceutical company’s stock worth $239,311,000 after purchasing an additional 2,317,676 shares during the period. TIG Advisors LLC increased its stake in Celgene by 77.3% in the second quarter. TIG Advisors LLC now owns 3,583,622 shares of the biopharmaceutical company’s stock worth $331,270,000 after purchasing an additional 1,562,004 shares during the period. Finally, Omni Partners LLP increased its stake in Celgene by 207.0% in the second quarter. Omni Partners LLP now owns 1,842,219 shares of the biopharmaceutical company’s stock worth $170,295,000 after purchasing an additional 1,242,219 shares during the period. Institutional investors own 72.47% of the company’s stock.

In other news, insider Terrie Curran sold 11,338 shares of the stock in a transaction on Wednesday, September 18th. The stock was sold at an average price of $98.27, for a total transaction of $1,114,185.26. Following the transaction, the insider now owns 13,493 shares of the company’s stock, valued at approximately $1,325,957.11. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. 0.39% of the stock is currently owned by corporate insiders.

CELG opened at $100.97 on Thursday. Celgene Co. has a 12-month low of $58.59 and a 12-month high of $101.22. The company has a current ratio of 3.44, a quick ratio of 3.32 and a debt-to-equity ratio of 1.97. The business’s fifty day simple moving average is $98.63 and its 200-day simple moving average is $95.40. The company has a market capitalization of $71.15 billion, a price-to-earnings ratio of 13.27, a PEG ratio of 0.51 and a beta of 1.42.

Celgene (NASDAQ:CELG) last posted its quarterly earnings results on Tuesday, July 30th. The biopharmaceutical company reported $2.61 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.44 by $0.17. Celgene had a return on equity of 89.93% and a net margin of 32.24%. The business had revenue of $4.40 billion for the quarter, compared to the consensus estimate of $4.22 billion. During the same quarter in the prior year, the company earned $2.16 EPS. The business’s revenue was up 15.4% compared to the same quarter last year. On average, equities research analysts predict that Celgene Co. will post 9.96 EPS for the current year.

A number of analysts have weighed in on the company. Mizuho lowered Celgene from a “buy” rating to a “neutral” rating and reduced their target price for the stock from $103.00 to $100.00 in a research note on Monday, August 19th. BidaskClub upgraded Celgene from a “hold” rating to a “buy” rating in a research note on Tuesday, October 1st. ValuEngine lowered Celgene from a “sell” rating to a “strong sell” rating in a research note on Thursday, August 1st. Zacks Investment Research upgraded Celgene from a “sell” rating to a “hold” rating and set a $94.00 target price on the stock in a research note on Tuesday, July 23rd. Finally, Cowen reiterated a “hold” rating and issued a $102.00 target price on shares of Celgene in a research note on Tuesday, July 30th. One research analyst has rated the stock with a sell rating, seventeen have issued a hold rating and four have issued a buy rating to the stock. The company has a consensus rating of “Hold” and an average target price of $94.60.

About Celgene

Celgene Corporation, a biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of cancer and inflammatory diseases worldwide. It offers REVLIMID, an oral immunomodulatory drug for multiple myeloma (MM), myelodysplastic syndromes (MDS), and mantle cell lymphoma; POMALYST/IMNOVID to treat multiple myeloma; OTEZLA, a small-molecule inhibitor of phosphodiesterase 4 for psoriatic arthritis and psoriasis; and ABRAXANE to treat breast, non-small cell lung, pancreatic, and gastric cancers.

Further Reading: Commodities

Want to see what other hedge funds are holding CELG? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Celgene Co. (NASDAQ:CELG).

Institutional Ownership by Quarter for Celgene (NASDAQ:CELG)

Receive News & Ratings for Celgene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene and related companies with MarketBeat.com's FREE daily email newsletter.